The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.
In August 2024, the Food and Drug Administration (FDA) approved denileukin diftitox-cxdl (Lymphir™) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
- No updates
Non-Hodgkin Lymphoma: In Detail
- No updates
- No updates